

Apr 03 07 11:39p

p. 4

Unknown

From: Mullen, Jamie A
Sent: Tuesday, January 25, 2005 4:24 PM
To: Daniels, Stephanie
Subject: RE: Reprints of Reinstein

Stephanie - This is the study. Goes to show you that if there's a huge need for data to support a message, the data will find its way out (despite our guidance to the contrary).

If you want to talk about the advice to provide Anders, I'd be happy to help you on the phone.

Jamie

-----Original Message-----

From: Daniels, Stephanie
Sent: Tuesday, January 25, 2005 11:30 AM
To: Mullen, Jamie A
Subject: FW: Reprints of Reinstein

Hi Jamie - is the Reinstein study the one we're not supposing to be using any more??

(Interestingly, Sweden were also asking about the Nagy study earlier in the week.)

Thanks

Stephanie

-----Original Message-----

From: Granö, Anders
Sent: Tue 25 Jan 2005 15:23
To: Daniels, Stephanie
Cc: Andersson, Britt-Marie A
Subject: Reprints of Reinstein


Dear Stephanie,

The study by Reinstein showing the favorable switch from clozapine to Seroquel has been very popular among Swedish psychiatrists. In fact, so popular that we have run out of copies. Do you know what the cost for further reprints would be and/or if maybe there is a "secret stash" somewhere?

Thank you in advance,

Anders Granö
Brand Manager Seroquel

AstraZeneca Sverige AB
B413 42C1 SE-151 65 Sodertälje Sweden
Tel +46 8 553 248 58 Fax +46 8 553 278 81 Mobile **REDACTED**
anders.grano@astrazeneca.com



2